2024-513549-36-01招募中1 期
A study to test how well different doses of BI 3804379 are tolerated by healthy people
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 106
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas2024-519301-36-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.40
招募中
1 期
This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)2024-511503-41-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.112
撤回
2 期
Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled CorticosteroidsAsthmaNCT01458912Boehringer Ingelheim
终止
2 期
Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).AsthmaNCT01396278Boehringer Ingelheim9
已完成
2 期
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 DiabetesDiabetes Mellitus, Type 2NCT00309608Boehringer Ingelheim333